Payment overview · 2025
General Payments
$549.97
23 reported records · 9 companies
Healthcare provider profile · identity verified
Timothy O Thomson, MD
Allopathic & Osteopathic Physicians|Family Medicine · THOMASVILLE, GA · NPI 1699858605
Verified facts
What the public records show
CMS Open Payments records show Timothy O Thomson, MD received $549.97 in general payments during 2025 across 23 reported records.
ABBVIE INC. accounted for 33.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Linzess, Mounjaro, Ozempic, Paxlovid, Rybelsus, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $185.66 | 33.8% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $99.05 | 18.0% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $73.97 | 13.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.92 | 10.0% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $38.06 | 6.9% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $31.32 | 5.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $25.41 | 4.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.65 | 3.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.93 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $549.97 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $137.05 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $73.97 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.82 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $48.61 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $48.61 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.23 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $38.06 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.79 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $31.32 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $25.41 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $16.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 84 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 53 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 172 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 14 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
204 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
172 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 499 | 141 |
| Amlodipine Besylate | Amlodipine Besylate | 413 | 110 |
| Losartan Potassium | Losartan Potassium | 287 | 71 |
| Lisinopril | Lisinopril | 245 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 219 | 65 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 214 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 214 | 49 |
| Jardiance | Empagliflozin | 204 | 48 |
| Tramadol Hcl | Tramadol Hcl | 199 | 55 |
| Clonazepam | Clonazepam | 195 | 27 |
| Gabapentin | Gabapentin | 180 | 43 |
| Metformin Hcl | Metformin Hcl | 173 | 49 |
| Ozempic | Semaglutide | 172 | 29 |
| Glipizide Er | Glipizide | 165 | 47 |
| Metformin Hcl Er | Metformin Hcl | 158 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 154 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 153 | 43 |
| Omeprazole | Omeprazole | 149 | 41 |
| Alprazolam | Alprazolam | 148 | 32 |
| Potassium Chloride | Potassium Chloride | 147 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 142 | 23 |
| Alendronate Sodium | Alendronate Sodium | 130 | 25 |
| Meloxicam | Meloxicam | 127 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 115 | 32 |
| Prednisone | Prednisone | 110 | 76 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 26 |
| Furosemide | Furosemide | 104 | 32 |
| Allopurinol | Allopurinol | 95 | 29 |
| Trazodone Hcl | Trazodone Hcl | 95 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 36 |
| Montelukast Sodium | Montelukast Sodium | 92 | 21 |
| Eliquis | Apixaban | 84 | 14 |
| Famotidine | Famotidine | 82 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 26 |
| Carvedilol | Carvedilol | 78 | 23 |
| Simvastatin | Simvastatin | 78 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 25 |
| Aripiprazole | Aripiprazole | 72 | 18 |
| Sertraline Hcl | Sertraline Hcl | 66 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 19 |
| Mirtazapine | Mirtazapine | 58 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 58 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 29 |
| Linzess | Linaclotide | 53 | 18 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 53 | 49 |
| Chlorthalidone | Chlorthalidone | 52 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | 18 |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 49 | 12 |
| Methylprednisolone | Methylprednisolone | 49 | 41 |
| Temazepam | Temazepam | 49 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 12 |
| Pregabalin | Pregabalin | 46 | suppressed |
| Azithromycin | Azithromycin | 45 | 37 |
| Lorazepam | Lorazepam | 45 | suppressed |
| Primidone | Primidone | 45 | 15 |
| Atenolol | Atenolol | 44 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Baclofen | Baclofen | 42 | 13 |
| Cephalexin | Cephalexin | 42 | 31 |
| Lovastatin | Lovastatin | 41 | 11 |
| Nystatin | Nystatin | 41 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Nifedipine Er | Nifedipine | 39 | 11 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Fluconazole | Fluconazole | 38 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 12 |
| Levemir Flexpen | Insulin Detemir | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | 11 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 35 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 30 |
| Celecoxib | Celecoxib | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Olanzapine | Olanzapine | 31 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 29 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 18 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Xifaxan | Rifaximin | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 18 |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 12 |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $549.97 · 23 records | ABBVIE INC. | AIRSUPRA, Auvelity, CREON, Dexcom G6 Transmitter, ELIQUIS, Fluad, Flucelvax, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, Rybelsus, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error